Mark Bamforth
Signal active
Operating Partner
Bio
Mark Bamforth is the Operating Partner at Ampersand Capital Partners.
Location
Boston, Massachusetts, United States, North America
Social
Primary Organization
Ampersand Capital Partners
Founded
1988
Investment
70
Lead investment
32
Exits
33
Employees
11-50
Industry
Financial Services, Venture Capital, Finance, Angel Investment, Health Care
Jobs history
6
Ampersand Capital Partners
Operating Partner
2018 - Current
Arranta Bio
Exec. Chair & CEO
2019 - 2022
Pneumagen
Board Member
2020 - Current
Board Member
2019 - Current
CONTINUUS Pharmaceuticals
Board Member
2019 - Current
Avid Biosciences
Board Member
2017 - Current
Board and Advisor Roles
0
N/A
Invest in regions
Profile Resume
Mark Bamforth is the Operating Partner at Ampersand Capital Partners, based in United States, North America. With a background in Financial Services, Mark Bamforth has a rich history of leadership and innovation. Mark Bamforth studied BS Chemical Engineering @ University of Strathclyde. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.
Recommendation from your interest
John Maraganore
CEO
George Church
Co-Founder
Philip Reilly
Venture Partner
N/A
Investment portfolio
Mark Bamforth has made 5 investments. Their Latest investment was Seed Round - Thymmune Therapeutics on Mar 01, 2023
Number of investment
5
Number of exits
0
Personal investment
5
| Annouced Date | Organization Name | Funding Round | Money Raised |
|---|---|---|---|
| Feb 01, 2022 | Talking Medicines | Venture Round - Talking Medicines | 2.0M |
| Jan 12, 2023 | PneumoWave | Series A - PneumoWave | 9.2M |
| Feb 01, 2023 | Dxcover | Series A - Dxcover | 9.3M |
| Mar 01, 2023 | Thymmune Therapeutics | Seed Round - Thymmune Therapeutics | 7.0M |
Partner investment
9
| Annouced Date | Organization Name | Funding Round | Investor Name | Money Raised |
|---|---|---|---|---|
| Jun 01, 2023 | Pneumagen | Venture Round - Pneumagen | Thairm Bio | 10.0M |
| Jan 22, 2024 | 3Daughters | Seed Round - 3Daughters | Thairm Bio | 2.0M |
| Apr 17, 2024 | - | Venture Round - Phlo | Thairm Bio | 11.2M |
| Jul 10, 2024 | 3Daughters | Seed Round - 3Daughters | Thairm Bio | 2.7M |
Exits
0
There is no exit available on this Profile
Invest in industries
Recent Activity
There is no recent news or activity for this profile.